EmbectavsJohnson & Johnson

EMBC and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

EMBC

Embecta Corp.

$6.19

Value $362M

+1.64%
EMBC's page

Embecta (EMBC) has a market value of $362M and Johnson & Johnson (JNJ) $644B. Over the last year, with dividends, EMBC moved -55.0% and JNJ +36.6%. The P/E is 4.1 for EMBC and 40.0 for JNJ. Dividend yield: EMBC 5.17%, JNJ 1.98%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    EMBC$362M

    JNJ$644B

    JNJ is 1,777 times EMBC

  • Revenue, 12 months

    EMBC$1.0B

    JNJ$99.3B

    JNJ is 98 times EMBC

  • Net income, 12 months

    EMBC$88M

    JNJ$16.1B

    JNJ is 184 times EMBC

  • Operating margin

    EMBC21.9%

    JNJ–

  • ROIC

    EMBC20.4%

    JNJ12.4%

    8.0 points apart

  • P/E

    EMBC4.1

    JNJ40.0

    JNJ is 9.7 times EMBC

  • Dividend yield

    EMBC5.2%

    JNJ2.0%

    3.2 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

EMBC-58.2%

JNJ+94.2%

100200202420252026
Returns by period
PeriodEMBCWith dividendsJNJWith dividends
1 year since November 18, 2025-55.0%Price -56.4%+36.6%Price +33.6%
3 years since November 17, 2023-58.2%-25.2% a yearPrice -62.8%+94.2%+24.8% a yearPrice +78.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

EMBCEmbectaJNJJohnson & Johnson

Valuation

EMBCJNJ
Valuation
Price$6.19$267.14
Market value$362M$644B
Enterprise value (EV)$1.6B$671B
P/E4.140.0
P/E, 5-year median9.621.9
P/B–7.9
EV/EBIT7.337.8
Free cash flow yield45.5%3.2%

Results and growth

EMBCJNJ
Results and growth
Revenue, 12 months$1.0B$99.3B
Net income, 12 months$88M$16.1B
Free cash flow, 12 months$165M$20.6B
Earnings per share, 12 months$1.47$6.59
Revenue growth, year on year-3.8%6.1%
Revenue growth a year, past-0.1%over 5 years+2.7%over 5 years
EPS growth a year, past-26.4%over 5 years+14.9%over 5 years

Margins and returns on capital

EMBCJNJ
Margins and returns on capital
Gross margin59.0%67.6%
Operating margin21.9%–
Net margin8.6%16.2%
ROIC20.4%12.4%
ROE–19.7%

Balance sheet

EMBCJNJ
Balance sheet
Cash$215M$17.2B
Total debt$1.5B$44.7B
Net debt / EBITDA4.81.1
Interest cover–18.0×

Dividends and buybacks

EMBCJNJ
Dividends and buybacks
Dividend yield5.2%2.0%
Dividend per share, 12 months$0.32$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield5.2%2.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: EMBC or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Embecta or Johnson & Johnson?

By market value, Johnson & Johnson ($644B) is about 1,777.4 times Embecta ($362M), at today's prices.

How did EMBC and JNJ stock do over the last 3 years?

Since November 17, 2023, EMBC's price moved -62.8% and JNJ's +78.3%. With dividends: EMBC -58.2% (-25.2% a year), JNJ +94.2% (+24.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, EMBC or JNJ?

The dividend yield at today's price is 5.17% for Embecta and 1.98% for Johnson & Johnson. Over the last twelve months they paid $0.32 and $5.28 per share.

What is the P/E of EMBC and JNJ?

At today's price, the P/E is 4.1 for EMBC and 40.0 for JNJ. The median of the last five years was 9.6 and 21.9, which shows where each stands against its own past.

Which has the higher profit margins, Embecta or Johnson & Johnson?

Over the last twelve months, the net margin was 8.6% for Embecta and 16.2% for Johnson & Johnson, and the operating margin 21.9% and –. Revenue was $1.0B and $99.3B.

Which is the better investment, Embecta or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.